| Gender |
|
|
0.644 |
| Female |
455 (38.9) |
203 (40.2) |
|
| Male |
716 (61.1) |
302 (59.8) |
|
| Age (year) [median (IQR)] |
63.00 (56.00, 69.00) |
62.00 (55.00, 67.00) |
0.090 |
| BMI (kg/m2) [median (IQR)]
|
22.43 (20.53, 24.22) |
22.34 (20.28, 24.22) |
0.883 |
| TBIL (μmol/L) [median (IQR)] |
19.90 (11.30, 109.30) |
18.10 (10.30, 116.09) |
0.470 |
| CA19-9 (U/mL) (median [IQR]) |
158.40 (38.89, 503.00) |
160.00 (41.00, 563.20) |
0.853 |
| CEA (ng/mL) [median (IQR)] |
3.24 (2.01, 5.65) |
3.30 (1.92, 5.59) |
0.985 |
| Tumor size (cm) [median (IQR)] |
3.00 (2.50, 4.00) |
3.00 (2.50, 4.00) |
0.843 |
| Site of tumor |
|
|
0.624 |
| Body and tail of pancreas |
369 (31.5) |
166 (32.9) |
|
| Head of pancreas |
802 (68.5) |
339 (67.1) |
|
| Differentiation |
|
|
0.641 |
| Well |
53 (4.5) |
21 (4.2) |
|
| Moderate |
557 (47.6) |
235 (46.5) |
|
| Poor |
558 (47.7) |
249 (49.3) |
|
| Undifferentiated |
3 (0.3) |
0 (0) |
|
| LNs positive [median (IQR)] |
0 (0, 1.00) |
0 (0, 1.00) |
0.751 |
| LNs examined [median (IQR)] |
10.00 (5.00, 16.00) |
10.00 (5.00, 16.00) |
0.771 |
| TNM |
|
|
0.621 |
| IA |
140 (12.0) |
70 (13.9) |
|
| IB |
329 (28.1) |
148 (29.3) |
|
| IIA |
130 (11.1) |
46 (9.1) |
|
| IIB |
350 (29.9) |
148 (29.3) |
|
| III |
222 (19.0) |
93 (18.4) |
|
| T stage |
|
|
0.710 |
| T1 |
213 (18.2) |
104 (20.6) |
|
| T2 |
606 (51.8) |
255 (50.5) |
|
| T3 |
213 (18.2) |
87 (17.2) |
|
| T4 |
139 (11.9) |
59 (11.7) |
|
| N stage |
|
|
0.653 |
| N0 |
666 (56.9) |
293 (58.0) |
|
| N1 |
401 (34.2) |
174 (34.5) |
|
| N2 |
104 (8.9) |
38 (7.5) |
|
| Margin |
|
|
0.035 |
| R0 |
1,062 (90.7) |
440 (87.1) |
|
| R1 |
109 (9.3) |
65 (12.9) |
|
| Adjuvant therapy |
|
|
0.810 |
| No |
663 (56.6) |
282 (55.8) |
|
| Yes |
508 (43.4) |
223 (44.2) |
|
